In summary, AVCRI104P4 exerts a significant cholinergic cognitive effect in a transgenic mouse model of AD but it has no effect on Aβ production (Aβ peptides levels) and aggregation (amyloid burden) either in APPSL mice or in C. elegans, contrary to our expectactions in the light of its in vitro multitarget profile including inhibition of BACE-1 and Aβ aggregation among other actions. Here, BACE1 is linked to Alzheimer disease.